Orencia
European Commission approves new RA treatment from BMS
September 6, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis
Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …
CHMP issues positive opinion for Orencia Rheumatoid Arthritis treatment
July 25, 2016Manufacturing and Production, Sales and Marketing BMS, CHMP, Orencia, rheumatoid arthritis
Bristol-Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion of …
New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs
December 16, 2015Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin
NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …
BMS backs rheumatoid arthritis prevention trial
March 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, Orencia, RA, abatacept, rheumatoid arthritis
Bristol-Myers Squibb is funding a £3 million trial of Orencia as a preventative treatment for rheumatoid arthritis. The study will …
BMS and Lonza announce expansion plans
October 31, 2014Manufacturing and Production, Sales and Marketing BMS, Lonza, Orencia, manufacturing, opdivo
Bristol-Myers Squibb (BMS) and Lonza are to expand upon an existing manufacturing agreement to meet anticipated demand for commercial biologics. …
Orencia matches Humira
June 13, 2013Sales and Marketing AbbVie, Abbott, Humira, Orencia, RA
Bristol-Myers Squibb is hoping its biologic Orencia can grab a little more of the rheumatoid arthritis market after demonstrating non-inferiority …
RoActemra superior to Humira as single-agent therapy
June 7, 2012Research and Development, Sales and Marketing Humira, Orencia, RA, RoActemra, Roche. ADACTA
Roche’s RoActemra (tocilizumab) is more effective in treating rheumatoid arthritis as a single agent than market leader Humira, a new …
NICE says no to BMS for second-line Orencia
August 25, 2011Sales and Marketing BMS, NICE, Orencia, rheumatoid arthritis
In final draft guidance NICE has not recommended the use of Bristol-Myers Squibb’s arthritis drug Orencia after other drugs have …
NICE re-thinks arthritis guidance
June 25, 2010Sales and Marketing Enbrel, Humira, MabThera, NICE, Orencia, Remicade, TNF, rheumatoid arthritis
NICE has approved five rheumatoid arthritis treatments in certain circumstances after treatment with a tumour necrosis factor inhibitor has failed. …
Orencia wins expanded European licence
January 27, 2010Sales and Marketing BMS, Orencia, rheumatoid arthritis
BMS’s Orencia has been approved in Europe to treat children aged six and over who suffer from a form of …
Latest content
Five Facts about cardiovascular disease
